Specialized palliative care in patients with haematological malignancies receiving chimeric antigen receptor T‐cell therapy-Reference-Cited by-同舟云学术

Specialized palliative care in patients with haematological malignancies receiving chimeric antigen receptor T‐cell therapy

Published:2024-03-24 Issue:1 Volume:205 Page:343-346
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Eichenauer Dennis A.¹^ORCID,Heger Jan‐Michel¹²^ORCID,Kruschel Isabel³,Kutsch Nadine¹^ORCID,Gödel Philipp¹,Garcia Borrega Jorge¹,Schnetzke Ulf⁴,Böll Boris¹^ORCID,Neumann Marie Anne‐Catherine¹,Gebel Cordula³,Pralong Anne⁵,Borchmann Peter¹,Voltz Raymond⁵,Wedding Ulrich³,Simon Steffen T.⁵

Affiliation:

1. First Department of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf University of Cologne Cologne Germany

2. Mildred Scheel School of Oncology Aachen Bonn Cologne Dusseldorf (MSSO ABCD) Faculty of Medicine and University Hospital Cologne Cologne Germany

3. Department of Palliative Care University Hospital Jena Jena Germany

4. Department of Internal Medicine II University Hospital Jena Jena Germany

5. Department of Palliative Medicine, Center for Integrated Oncology Aachen Bonn Cologne Dusseldorf Faculty of Medicine and University Hospital Cologne Cologne Germany

Funder

Deutsche Krebshilfe

Publisher

Wiley

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/bjh.19434

Reference15 articles.

1. Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

2. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

3. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

4. Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma

5. Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis